Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2311 to 2325 of 7681 results

  1. Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070]

    In development [GID-TA11042] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer ID 6471

    Awaiting development [GID-TA11490] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency ID 6466

    Awaiting development [GID-TA11583] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment ID 6467

    Awaiting development [GID-TA11585] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant ID 6468

    Awaiting development [GID-TA11581] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

    Awaiting development [GID-TA11008] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430

    Awaiting development [GID-TA11530] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker ID 6469

    Awaiting development [GID-TA11575] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]

    Awaiting development [GID-TA11360] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]

    Awaiting development [GID-TA11284] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

    Register an interest in this interventional procedure The National Institute for Health and Clinical Excellence (NICE) issued full guid...

    Interventional procedures guidance
    Topic selection

  12. Vamorolone for treating Duchenne muscular dystrophy [ID4024]

    In development [GID-TA11135] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

    Awaiting development [GID-TA10638] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]

    In development [GID-TA11298] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer ID 6472

    Awaiting development [GID-TA11589] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development